Vermillion (VRML) Receiving Somewhat Favorable Media Coverage, Analysis Shows

News articles about Vermillion (NASDAQ:VRML) have trended somewhat positive on Saturday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vermillion earned a news impact score of 0.02 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.1530542716533 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Vermillion (NASDAQ VRML) opened at $1.79 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.74 and a quick ratio of 3.67. Vermillion has a 12 month low of $0.91 and a 12 month high of $2.85.

Vermillion (NASDAQ:VRML) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.02). The company had revenue of $0.70 million during the quarter. Vermillion had a negative net margin of 332.10% and a negative return on equity of 200.44%.

VRML has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Vermillion from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Canaccord Genuity reiterated a “buy” rating and issued a $1.75 price objective (down previously from $2.50) on shares of Vermillion in a research note on Wednesday, August 30th.

ILLEGAL ACTIVITY NOTICE: “Vermillion (VRML) Receiving Somewhat Favorable Media Coverage, Analysis Shows” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at

Vermillion Company Profile

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

Insider Buying and Selling by Quarter for Vermillion (NASDAQ:VRML)

Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply